Cell Cure Neurosciences was founded as a subsidiary of Singapore-based ES Cell International (ESI). In 2010, BioTime acquired a majority interest in Cell Cure Neurosciences upon the acquisition of ESI. That transaction, along with other acquisitions of BioTime such as the stem cell assets of Geron Corporation, have resulted in an international consolidation of critical intellectual property rights within the BioTime family of companies. Cell Cure Neurosciences has an exclusive license option agreement with Teva Pharmaceutical Industries to develop and commercialize OpRegen® for the treatment of Age Relate Macular Degeneration (AMD). Teva Pharmaceutical has an option to obtain an exclusive license to OpRegen®, linked to responsibility for funding clinical trials, obtaining regulatory approvals and marketing the product.